470
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia

, , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 328-334 | Received 21 Dec 2014, Accepted 11 Jun 2015, Published online: 28 Sep 2015

References

  • Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
  • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
  • Fischer K, Bahlo J, Fink A-M, et al. Extended follow up of the CLL 8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR Regimen. ASH Annual Meeting Abstracts Blood 2012;120: Abstract 435.
  • Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578–4584.
  • Lepretre S, Aurran T, Mahe B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119:5104–5110.
  • Faderl S, Wierda W, O’Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 years. Leuk Res 2010;34:284–288.
  • Reynolds C, Di Bella N, Lyons RM, et al. A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012;30:1232–1240.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209–3216.
  • Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498–503.
  • Shah N, Tam C, Seymour JF, et al. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma 2015:56:1599–1610.
  • Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
  • Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640–1645.
  • Fortin M, Hudon C, Dubois MF, et al. Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health Qual Life Outcomes 2005;3:74.
  • Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999;17:1574–1579.
  • Cazin B, Divine M, Lepretre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54–59.
  • Dearden CE, Richards S, Else M, et al. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. Cancer 2011;117:2452–2460.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
  • Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910–1916.
  • Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:1947–1950.
  • Strati P, Wierda W, Burger J, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 2013;119:3805–3811.
  • Mulligan SP, Gill D, Turner P, et al. A randomised dose de-escalation study of oral fludara bine, ± oral cyclophosphamide and intravenous rituximab as first–line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥ 65 years: final analysis of response and toxicity. ASH Annual Meeting Abstracts, Blood 2014;124: Abstract 3325.
  • Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res 2014;38:891–895.
  • Smolej L, Brychtova Y, Cmunt E, et al. Low-dose FCR in elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: predictors of progression-free survival. Pjoject Q-lite by Czech CLL study group. XV iwCLL Abstracts 2013;4:40.
  • Lepretre S, Jager U, Janssens A, et al. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leuk Lymphoma 2012;53:820–829.
  • Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27:142–149.
  • Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1110.
  • Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood 2013;122:Abstract 528.
  • Shanafelt T, Lanasa MC, Call TG, et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 2013;119:3788–3796.
  • Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980–988.
  • Janssens A, Boogaerts M, Verhoef G. Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. Drug Des Devel Ther 2009;3:241–252.
  • Strati P, Keating MJ, O’Brien SM, et al. Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic leukemia. Blood 2014;123:3727–3732.
  • Byrd JC, Jones JJ, Woyach JA, et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 2014;32:3039–3047.
  • O’Brien SM, Furman RR, Byrd JC, et al. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol 2014;12:1–13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.